News | December 23, 2025
Cupid reduces promoter pledged stake to 20%
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Subscribe To Our Newsletter & Stay Updated
